RT Journal Article
SR Electronic
T1 SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.28.20200915
DO 10.1101/2020.09.28.20200915
A1 Bolotin, Shelly
A1 Tran, Vanessa
A1 Osman, Selma
A1 Brown, Kevin A.
A1 Buchan, Sarah A.
A1 Joh, Eugene
A1 Deeks, Shelley L.
A1 Allen, Vanessa G.
YR 2020
UL http://medrxiv.org/content/early/2020/09/29/2020.09.28.20200915.abstract
AB We analyzed 21,676 residual specimens from Ontario, Canada collected between March-August, 2020 to investigate the effect of antibody decline on SARS-CoV-2 seroprevalence estimates. Testing specimens orthogonally using the Abbott (anti-nucleocapsid) and then the Ortho (anti-spike) assays, seroprevalence estimates ranged from 0.4%-1.4%, despite ongoing disease activity. The geometric mean concentration (GMC) of antibody-positive specimens decreased over time (p=0.015), and the GMC of antibody-negative specimens increased over time (p=0.0018). The association between the two tests decreased each month (p<0.001), suggesting anti-N antibody decline. Lowering the Abbott index cut-off from 1.4 to 0.7 resulted in a 16% increase in positive specimens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Public Health Ontario and by the Canada COVID-19 Immunity Task Force.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for the Ontario population serosurveys was granted by the Public Health Ontario Ethics Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.